Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Ophthalmology and Therapy
Published in: Ophthalmology and Therapy 1/2016

Open Access 01-06-2016 | Review

Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections

Authors: Francis S. Mah, Christine M. Sanfilippo

Published in: Ophthalmology and Therapy | Issue 1/2016

Login to get access

Abstract

This comprehensive review summarizes the mechanism of action, pharmacokinetics, efficacy, and safety of besifloxacin ophthalmic suspension, 0.6% and examines its role in the treatment of ocular surface bacterial infections. Besifloxacin possesses balanced activity against bacterial topoisomerase II (also called DNA gyrase) and topoisomerase IV. It has shown a low potential to select for bacterial resistance in vitro and demonstrated strong in vitro activity against many Gram-positive, Gram-negative, and anaerobic organisms, including methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis (MRSA and MRSE, respectively). Ocular pharmacokinetic studies have shown that besifloxacin achieves high, sustained concentrations in the tear fluid and conjunctiva following topical administration, with negligible systemic exposure. Large randomized, controlled clinical trials have established the efficacy and safety of besifloxacin administered three times daily for 5 days for treatment of acute bacterial conjunctivitis in both adults and children, with high rates of clinical resolution (up to more than 70% by day 5) and bacterial eradication (more than 90% by day 5), and a low incidence of adverse events. Additionally, besifloxacin applied twice daily for 3 days demonstrated greater efficacy than vehicle in treating bacterial conjunctivitis. Case reports, a large retrospective chart review, and animal studies have provided supporting evidence for the efficacy of besifloxacin in the management of acute bacterial keratitis. There is some evidence to suggest that besifloxacin may provide an advantage over other current-generation fluoroquinolones in antimicrobial prophylaxis for ocular surgery. Besifloxacin is an appropriate option for treatment of bacterial conjunctivitis, and its use in the treatment of bacterial keratitis and lid disorders, as well as for surgical prophylaxis, appears promising and warrants further evaluation.
Literature
1.
Andriole VT. The quinolones: past, present, and future. Clin Infect Dis. 2005;41(Suppl 2):S113–9.CrossRefPubMed
2.
O’Brien TP. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther. 2012;29(6):473–90.CrossRefPubMed
3.
Jensen HG, Felix C. In vitro antibiotic susceptibilities of ocular isolates in North and South America. Vitro Antibiotic Testing Group. Cornea. 1998;17(1):79–87.CrossRefPubMed
4.
Haas W, Sanfilippo CM, Hesje CK, Morris TW. Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones. Clin Ophthalmol. 2013;7:821–30.CrossRefPubMedPubMedCentral
5.
Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009;53(8):3552–60.CrossRefPubMedPubMedCentral
6.
Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004;49(Suppl 2):S73–8.CrossRefPubMed
7.
Reed KK. How to managed bacterial eye infections: bacterial eye infections can have visually devastating consequences. But, the proper use of anti-infectives and antibiotic-steroid combination agents can protect your patients’ sight. Rev Optometry. 2011;148(5):84.
8.
McDonald MD, Blondeau JM. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones. J Cataract Refract Surg. 2010;36:1588–98.CrossRefPubMed
9.
Miller D, Flynn PM, Scott IU, Alfonso EC, Flynn HW. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol. 2006;124:479–83.CrossRefPubMed
10.
Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008;145(6):951–8.CrossRefPubMed
11.
Asbell PA, Sahm DF, Shaw M, Draghi DC, Brown NP. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J Cataract Refract Surg. 2008;34(5):814–8.CrossRefPubMed
12.
Cavuoto K, Zutshi D, Karp CL, Miller D, Feuer W. Update on bacterial conjunctivis in South Florida. Ophthalmology. 2008;115:51–6.CrossRefPubMed
13.
Adebayo A, Parikh JG, McCormick SA, et al. Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctivitis isolates in the last decade at the New York Eye and Ear Infirmary. Graefes Arch Clin Exp Ophthalmol. 2011;249:111–9.CrossRefPubMed
14.
Asbell PA, Sanfilippo CM, Pillar CM, DeCory HH, Sahm DF, Morris TW. Antibiotic resistance among ocular pathogens in the United States: five-year results from the ARMOR surveillance study. JAMA Ophthalmol. 2015;133(12):1445–54.CrossRefPubMed
15.
BESIVANCE® package insert. Tampa, FL: Bausch & Lomb Incorporated; 2012.
16.
BESIVANCE™ product monograph. Vaughan: Bausch & Lomb Canada Inc.; 2009.
17.
Ward KH, Lepage J-F, Driot J-Y. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther. 2007;23:243–56.CrossRefPubMed
18.
Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science. 1992;257:1050–5.CrossRefPubMed
19.
20.
21.
Levine C, Hiasa H, Marians K. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim Biophys Acta. 1998;1400:29–43.CrossRefPubMed
22.
23.
Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones: place in ocular therapy. Drugs. 2001;61:747–61.CrossRefPubMed
24.
Fisher LM, Heaton VJ. Dual activity of fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother. 2003;51:463–4.CrossRefPubMed
25.
Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. J Antimicrob Chemother. 2002;49:893–5.CrossRefPubMed
26.
Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45(2):433–8.CrossRefPubMedPubMedCentral
27.
Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009;63(3):443–50.CrossRefPubMed
28.
Zhang JZ, Cavet ME, Ward KW. Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells. Curr Eye Res. 2008;33(11):923–32.CrossRefPubMed
29.
Zhang JZ, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008;61(1):111–6.CrossRefPubMed
30.
31.
Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother. 2000;46:17–24.CrossRefPubMed
32.
33.
Scoper SV. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in vitro and in vivo efficacy. Adv Ther. 2008;25(10):979–94.CrossRefPubMed
34.
Haas W, Gearinger LS, Usner DW, Decory HH, Morris TW. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol 2011;5:1369–79.
35.
Miller D, Chang JS, Flynn HW, Alfonso EC. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci. J Ocul Pharmacol Ther. 2013;29(3):339–44.CrossRefPubMed
36.
Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother. 2010;65(7):1441–7.CrossRefPubMedPubMedCentral
37.
Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW. In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride. J Antimicrob Chemother. 2011;66(4):840–4.CrossRefPubMed
38.
39.
Ferrero L, Cameron B, Manse B, et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol. 1994;13:64≤1–653.CrossRef
40.
Sanfilippo CM, Hesje CK, Haas W, Morris TW. Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin. Chemotherapy. 2011;57(5):363–71.CrossRefPubMed
41.
42.
Shinabarger DL, Zurenko GE, Hesje CK, Sanfilippo CM, Morris TW, Haas W. Evaluation of the effect of bacterial efflux pumps on the antibacterial activity of the novel fluoroquinolone besifloxacin. J Chemother. 2011;23(2):80–6.CrossRefPubMed
43.
Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009;25(4):335–44.CrossRefPubMed
44.
Glogowski S, Ward KW, Lawrence MS, Goody RJ, Proksch JW. The use of the African green monkey as a preclinical model for ocular pharmacokinetic studies. J Ocul Pharmacol Ther. 2012;28(3):290–8.CrossRefPubMed
45.
Arnold DR, Granvil CP, Ward KW, Proksch JW. Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867(1):105–10.CrossRefPubMed
46.
Protzko E, Bowman L, Abelson M. Shapiro A; AzaSite Clinical Study Group. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007;48:3425–9.CrossRefPubMed
47.
Proksch JW, Ward KW. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits. J Ocul Pharmacol Ther. 2010;26(5):449–58.CrossRefPubMed
48.
Torkildsen G, Proksch JW, Shapiro A, Lynch SK, Comstock TL. Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. Clin Ophthalmol. 2010;4:331–41.PubMedPubMedCentral
49.
Yoshida J, Kim A, Pratzer KA, Stark WJ. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients. J Cataract Refract Surg. 2010;36(9):1499–502.CrossRefPubMed
50.
Scassellati Sforzolini B, Sheets JW Jr, Morris TW. Relevance of aqueous humor concentrations of fluoroquinolones. J Cataract Refract Surg. 2011;37(1):217–8.
51.
Donnenfeld ED, Comstock TL, Proksch JW. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. J Cataract Refract Surg. 2011;37(6):1082–9.CrossRefPubMed
52.
Evans R, Bucci F. The Pharmacokinetics and Aqueous Humor Penetration of Besifloxacin 0.6% and Moxifloxacin 0.5% in Patients Undergoing Cataract Surgery. Invest Ophthalmol Vis Sci. 2013;54(15):4290.
53.
Chung JL, Lim EH, Song SW, Kim BY, Lee JH, Mah FS, Seo KY. Comparative intraocular penetration of 4 fluoroquinolones after topical instillation. Cornea. 2013;32(7):1046–51.CrossRefPubMed
54.
55.
Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2012;9:CD001211.PubMed
56.
Karpecki P, Depaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31(3):514–26.CrossRefPubMed
57.
Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25(5):1159–69.CrossRefPubMed
58.
McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009;116(9):1615–23.CrossRefPubMed
59.
DeLeon J, Silverstein BE, Allaire C, et al. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children. Clin Drug Investig. 2012;32(5):303–17.CrossRefPubMed
60.
Garg P, Mathur U, Sony P, et al. Clinical and antibacterial efficacy and safety of besifloxacin ophthalmic suspension compared with moxifloxacin ophthalmic solution. Asia-Pacif J Ophthalmol 2015;4(3):140–5.CrossRef
61.
Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Paediatr Drugs. 2010;12(2):105–12.CrossRefPubMed
62.
Ong T, Allaire C, Morris TW, Sforzolini B. Besifloxacin ophthalmic suspension, 0.6% compared with gatifloxacin ophthalmic solution, 0.3% for the treatment of bacterial conjunctivitis in neonatal patients. Invest Ophthalmol Vis Sci. 2014;55(13):5790.
63.
Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008;27:22–7.CrossRefPubMed
64.
Turaka K, Penne RB, Rapuano CJ, et al. Giant fornix syndrome: a case series. Ophthal Plast Reconstr Surg. 2012;28(1):4–6.CrossRefPubMed
65.
Silverstein BE, Morris TW, Gearinger LS, Decory HH, Comstock TL. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections. Clin Ophthalmol. 2012;6:1987–96.PubMedPubMedCentral
66.
Comstock TL, Morris TW, Gearinger LS, DeCory HH. Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens. Clin Ophthalmol. 2014;6:25–35.
67.
Michaud L. Efficacy of besifloxacin in the treatment of corneal ulcer. Clin Refract Optom. 2011;22:90–3.
68.
69.
Schechter BA, Parekh JG, Trattler W. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study. J Ocul Pharmacol Ther. 2015;31(2):114–21.CrossRefPubMed
70.
Sanders ME, Moore QC 3rd, Norcross EW, Shafiee A, Marquart ME. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. J Ocul Pharmacol Ther. 2010;26(2):193–8.CrossRefPubMed
71.
Sanders ME, Norcross EW, Moore QC 3rd, Shafiee A, Marquart ME. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis. Cornea. 2009;28(9):1055–60.CrossRefPubMed
72.
Sanders ME, Moore QC 3rd, Norcross EW, et al. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis. Cornea. 2011;30(1):83–90.CrossRefPubMed
73.
Packer M, Chang DF, Dewey SH, For the ASCRS Cataract Clinical Committee, et al. Prevention, diagnosis and management of acute postoperative bacterial endophthalmitis. J Cataract Refract Surg. 2011;37:1699–714.CrossRefPubMed
74.
Miller JJ, Scott IU, Flynn HW Jr, Smiddy WE, Newton J, Miller D. Acute–onset endophthalmitis after cataract surgery (2000–2004): incidence, clinical settings, and visual outcomes after treatment. Am J Ophthalmol. 2005;139:983–7.CrossRefPubMed
75.
Chang DF, Braga-Mele R, Mamalis N, et al. ASCRS Cataract Clinical Committee. Prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2007 ASCRS member survey. J Cataract Refract Surg. 2007;33(10):1801–5.CrossRefPubMed
76.
Moshirfar M, Feiz V, Vitale AT, Wegelin JA, Basavanthappa S, Wolsey DH. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series. Ophthalmology. 2007;114:686–91.CrossRefPubMed
77.
Jensen MK, Fiscella RG, Moshirfar M, Mooney B. Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years. J Cataract Refract Surg. 2008;34:1460–7.CrossRefPubMed
78.
Gentile RC, Shukla S, Shah M, et al. Microbiological spectrum and antibiotic sensitivity in endophthalmitis: a 25-year review. Ophthalmology. 2014;121(8):1634–42.CrossRefPubMed
79.
Chen X, Adelman RA. Microbial spectrum and resistance patterns in endophthalmitis: a 21-year (1988–2008) review in northeast United States. J Ocul Pharmacol Ther. 2012;28(4):329–34.CrossRefPubMed
80.
Bucci FA Jr, Evans RE, Amico LM, et al. Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery. Clin Ophthalmol. 2015;9:843–52.CrossRefPubMedPubMedCentral
81.
Malhotra R, Gira J, Berdy GJ, Brusatti R. Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study. Clin Ophthalmol. 2012;6:855–63.CrossRefPubMedPubMedCentral
82.
Parekh JG, Newsom TH, Nielsen S. Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients. J Cataract Refract Surg. 2012;38(10):1864–7.CrossRefPubMed
83.
Nielsen SA, McDonald MB, Majmudar PA. Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients. Clin Ophthalmol. 2013;7:149–56 Erratum in: Clin Ophthalmol. 2013;7:725.PubMedPubMedCentral
84.
Donnenfeld E, Lane S, Holland E, et al. A Prospective, Contralateral Eye, Double-Masked Study of the Effect of Besifloxacin 0.6% and Moxifloxacin 0.5% on Corneal Epithelial Wound Healing Following Photorefractive Keratectomy. Paper presented at Annual Meeting of the American Society of Cataract and Refractive Surgery (ASCRS). 2013.
85.
86.
John G. A comparative study in the clinical and microbial efficacy of topical besifloxocin ophthalmic suspension 0.6% with erythromycin ophthalmic ointment 0.5% for management of acute blepharitis. Invest Ophthalmol Vis Sci. 2012;53(14):6263.
87.
Tu Y, Boschert K, Schwab J, Wagner R, DeRespinis P, Guo S. Management of Congenital nasolacrimal duct obstruction with infection in infants using besifloxacin-a prospective study. Invest Ophthalmol Vis Sci. 2015;56(7):4870.
88.
Tu Y, Boschert K, Schwab J, Wagner R, DeRespinis P, Guo S. Comparison of besifloxacin and polymyxin–trimethoprim in treating congenital nasolacrimal duct obstruction with infection in children. Paper presented at: American Society of Cataract and Refractive Surgery Annual Symposium and Congress (ASCRS); 2015 April 20; San Diego.
89.
Comstock TL, Paterno MR, Decory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Clin Drug Investig. 2010;30(10):675–85.CrossRefPubMed
90.
Malhotra R, Ackerman S, Gearinger LS, Morris TW, Allaire C. The safety of besifloxacin ophthalmic suspension 0.6% used three times daily for 7 days in the treatment of bacterial conjunctivitis. Drugs R D. 2013;13(4):243–52.CrossRefPubMedPubMedCentral
91.
Talamo JH, Hatch KM, Woodcock EC. Delayed epithelial closure after PRK associated with topical besifloxacin use. Cornea. 2013;32(10):1365–8.CrossRefPubMed
92.
93.
Krenzer KL, Zhang JZ, Coffey MJ, Richardson ME. Safety of repeated topical ocular administration of a polycarbophil-based formulation in several models of ocular surgery in rabbits. J Cataract Refract Surg. 2012;38(4):696–704.CrossRefPubMed
94.
Zhang JZ, Krenzer KL, López FJ, Ward KW. Comparative effects of besifloxacin and other fluoroquinolones on corneal reepithelialization in the rabbit. J Cataract Refract Surg. 2010;36(6):1049–50.CrossRefPubMed
95.
Ness PJ, Mamalis N, Werner L, et al. An anterior chamber toxicity study evaluating Besivance, AzaSite, and Ciprofloxacin. Am J Ophthalmol. 2010;150(4):498–504.CrossRefPubMed
96.
Goecks T, Werner L, Mamalis N, et al. Toxicity comparison of intraocular azithromycin with and without a bioadhesive delivery system in rabbit eyes. J Cataract Refract Surg. 2012;38(1):137–45.CrossRefPubMed
Metadata
Title
Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
Authors
Francis S. Mah
Christine M. Sanfilippo
Publication date
01-06-2016
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 1/2016
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-016-0046-6

Other articles of this Issue 1/2016

Ophthalmology and Therapy 1/2016 Go to the issue

Case Series

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN®) in Patients with Diabetic Macular Edema: 10 Eyes with 12 Months Follow-up

Case Series

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN®) in Patients with Diabetic Macular Edema

Review

The Treatment Paradigm for the Implantable Miniature Telescope

Case Report

Nd:YAG Laser Hyaloidotomy for the Treatment of Acute Subhyaloid Hemorrhage: A Comparison of Two Cases

Original Research

Pharmacological Treatment of Presbyopia by Novel Binocularly Instilled Eye Drops: A Pilot Study

Review

Solid Platelet Rich Plasma in Corneal Surgery

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits